| 14.98 -1.04 (-6.49%) | 07-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 17.84 |
1-year : | 18.92 |
| Resists | First : | 15.27 |
Second : | 16.2 |
| Pivot price | 14.8  |
|||
| Supports | First : | 13.77 |
Second : | 11.46 |
| MAs | MA(5) : | 15.39 |
MA(20) : | 14.72 |
| MA(100) : | 14.33 |
MA(250) : | 10.71 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 69.9 |
D(3) : | 76.3 |
| RSI | RSI(14): 50.2 |
|||
| 52-week | High : | 17.35 | Low : | 5.67 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BWAY ] has closed below upper band by 41.7%. Bollinger Bands are 13.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.7 - 15.78 | 15.78 - 15.85 |
| Low: | 14.68 - 14.77 | 14.77 - 14.87 |
| Close: | 14.81 - 14.96 | 14.96 - 15.1 |
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Sat, 04 Jul 2026
BWAY - Brainsway Ltd ADR Options - Finviz
Fri, 03 Jul 2026
BWAY - Brainsway Ltd ADR Latest SEC Filings - Finviz
Mon, 29 Jun 2026
Deep TMS shows strong PTSD and depression response in BrainsWay (NASDAQ: BWAY) study - Stock Titan
Mon, 22 Jun 2026
Brainsway (BWAY) CTO sells 5,000 shares after exercising options - Stock Titan
Mon, 22 Jun 2026
BrainsWay wins South Carolina policy, lifting TMS coverage to 57M lives - Stock Titan
Mon, 22 Jun 2026
57M now covered for BrainsWay (NASDAQ: BWAY) accelerated Deep TMS - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 40 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 6 (%) |
| Held by Institutions | 29.8 (%) |
| Shares Short | 125 (K) |
| Shares Short P.Month | 132 (K) |
| EPS | 0.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.99 |
| Profit Margin | 15.5 % |
| Operating Margin | 12.9 % |
| Return on Assets (ttm) | 3.3 % |
| Return on Equity (ttm) | 12.5 % |
| Qtrly Rev. Growth | 34.5 % |
| Gross Profit (p.s.) | 1.05 |
| Sales Per Share | 1.4 |
| EBITDA (p.s.) | 0.16 |
| Qtrly Earnings Growth | 200 % |
| Operating Cash Flow | 14 (M) |
| Levered Free Cash Flow | 3 (M) |
| PE Ratio | 68.09 |
| PEG Ratio | 0 |
| Price to Book value | 7.52 |
| Price to Sales | 10.69 |
| Price to Cash Flow | 44.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|